Skip to main content

Free Content Bubble continuous positive airway pressure in a human immunodeficiency virus-infected infant [Case study]

Download Article:
(PDF 728.1298828125 kb)
World Health Organization-classified very severe pneumonia due to Pneumocystis jirovecii infection is recognized as a life-threatening condition in human immunodeficiency virus (HIV) infected infants. We recount the use of nasal bubble continuous positive airway pressure (BCPAP) in an HIV-infected African infant with very severe pneumonia and treatment failure due to suspected infection with P. jirovecii. We also examine the potential implications of BCPAP use in resource-poor settings with a high case index of acute respiratory failure due to HIV-related pneumonia, but limited access to mechanical ventilation.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: BCPAP; HIV; Pneumocystis jirovecii pneumonia; early infant diagnosis; sub-Saharan Africa

Document Type: Short Communication

Affiliations: 1: Department of Pediatrics, Kamuzu Central Hospital, Lilongwe, Malawi; and University of North Carolina Project, Lilongwe, Malawi 2: Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA 3: Baylor International Pediatric AIDS Initiative, Lilongwe, Malawi

Publication date: 2011-04-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more